- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04831840
Recurrent Urinary Tract Infections and the Microbiome
May 18, 2024 updated by: Laura Martin, University of Miami
Is PCR Amplification More Sensitive Than Urine Cultures in Diagnosing Urinary Tract Infections in Patients With Recurrent Bladder Infections?
The primary objective is to determine if polymerase chain reaction (PCR) (UTIP™) is more sensitive in identifying urinary tract infections (UTI's) than standard urine cultures.
Study Overview
Status
Terminated
Conditions
Study Type
Observational
Enrollment (Actual)
32
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Fort Lauderdale, Florida, United States, 33301
- Holy Cross Hospital
-
Miami, Florida, United States, 33136
- University of Miami
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 90 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Sampling Method
Non-Probability Sample
Study Population
Female patients with RUTIs and controls will be enrolled from University of Miami's or Holy Cross Hospital's female pelvic medicine and reconstructive surgery clinics.
Description
Inclusion Criteria:
- 18 y/o-90 y/o
- Able to consent
- Female
- Group A only: Recurrent UTI (2 UTIs in 6 months)
- Group B only: No history of recurrent UTIs
Exclusion Criteria:
- Pregnant
- Pelvic radiation
- Urinary retention (>200 ml residual)
- Greater than Stage 2 prolapse
- Renal calculi
- Immunosuppressed
- Neurologic disorder with significant bladder impairment
- No current UTI via dip stick
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
Female participants with recurrent urinary tract infections (RUTI).
Patients with RUTIs (Group A) will provide two urine samples.
One urine sample is a clean catch and the other is a catheterized specimen.
Both will be sent for analysis.
A perineal swab will also be collect and analyzed for each patient.
|
|
Female control patients without RUTIs
Patients without RUTIs (Group B) will provide two urine samples.
One urine sample is a clean catch and the other is a catheterized specimen.
Both will be sent for analysis.
A perineal swab will also be collect and analyzed for each patient.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of uropathogens
Time Frame: Day 1
|
The proportion of uropathogens found on PCR versus urine culture from urine samples.
|
Day 1
|
|
Proportion of patients negative for repeat testing
Time Frame: Up to 4 weeks
|
The proportion of negative patient on repeat testing of urine samples.
|
Up to 4 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Laura Martin, DO, University of Miami
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 26, 2021
Primary Completion (Actual)
November 20, 2023
Study Completion (Actual)
November 20, 2023
Study Registration Dates
First Submitted
April 2, 2021
First Submitted That Met QC Criteria
April 2, 2021
First Posted (Actual)
April 5, 2021
Study Record Updates
Last Update Posted (Actual)
May 21, 2024
Last Update Submitted That Met QC Criteria
May 18, 2024
Last Verified
May 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20201198
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent Urinary Tract Infection
-
University of Texas Southwestern Medical CenterRecruitingRecurrent Urinary Tract Infection | UTI | UTI - Lower Urinary Tract Infection | Recurrent UTIs | Recurrent Urinary Tract Infections | Cystitis Recurrent | Recurrent Urinary Tract Infections in Women | UTI - Urinary Tract Infection | Cystitis ChronicUnited States
-
Lawson Health Research InstituteUniversity of Western Ontario, CanadaCompletedUrinary Tract Infection | Recurrent Urinary Tract InfectionCanada
-
University of California, IrvineCompletedRecurrent Urinary Tract InfectionUnited States
-
University of SulaimaniCompletedRecurrent Urinary Tract InfectionIraq
-
IRCCS Policlinico S. MatteoCompleted
-
Beijing Institute of Disease Control and PreventionUnknownRecurrent Urinary Tract InfectionChina
-
University of California, San DiegoNYU Langone Health; American Urogynecologic SocietyCompletedRecurrent Urinary Tract InfectionUnited States
-
Hvidovre University HospitalRecruitingRecurrent Urinary Tract InfectionDenmark
-
Atlantic Health SystemNot yet recruitingRecurrent Urinary Tract Infection
-
Medical University of GrazCompletedRecurrent Urinary Tract InfectionAustria